Journal
GENE THERAPY
Volume 10, Issue 16, Pages 1275-1281Publisher
NATURE PUBLISHING GROUP
DOI: 10.1038/sj.gt.3302092
Keywords
lysosomal storage disorders; lysosomal enzymes; metabolic diseases; central nervous system; depot organs
Ask authors/readers for more resources
Despite disappointments with early clinical studies, there is continued interest in the development of gene therapy for the group of metabolic diseases referred to as lysosomal storage disorders (LSDs). The LSDs are monogenic and several small and large, representative animal models of the human diseases are available. Further, the successful reconstitution of only low and unregulated tissue levels of the affected lysosomal enzymes are expected to be sufficient to correct the disease at least in the case of some of the LSDs. For these reasons, they are perceived as good models for the evaluation of different gene delivery vectors and of different strategies for treating chronic genetic diseases by gene transfer. In this review, we will highlight the progress that has been made over the past 2 years in preclinical research for this group of disorders and speculate on future prospects.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available